Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Jul 15, 2019; 11(7): 551-566
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.551
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.551
Table 1 TYMS polymorphisms’ groups according to risk group and level of expression respectively
| Groups | Polymorphisms |
| 3’UTR | |
| A (low risk) | del/del |
| del/LOH | |
| ins/del | |
| ins/ins | |
| B (high risk) | ins/LOH |
| 5’UTR | |
| A (low expression) | 2RG |
| 2RG/3RC | |
| 3RC | |
| B (medium expression) | 2RG/3RG |
| 2RG/3RCLOH | |
| 2RG/3RGLOH | |
| 2RGLOH/3RC | |
| C (high expression) | 3RG |
| 3RG/3RC | |
| 2RGLOH/3RG |
- Citation: Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J Gastrointest Oncol 2019; 11(7): 551-566
- URL: https://www.wjgnet.com/1948-5204/full/v11/i7/551.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i7.551